HRP20161541T1 - Fuzionirani biciklični oksazolidinon kao inhibitor cetp - Google Patents
Fuzionirani biciklični oksazolidinon kao inhibitor cetp Download PDFInfo
- Publication number
- HRP20161541T1 HRP20161541T1 HRP20161541TT HRP20161541T HRP20161541T1 HR P20161541 T1 HRP20161541 T1 HR P20161541T1 HR P20161541T T HRP20161541T T HR P20161541TT HR P20161541 T HRP20161541 T HR P20161541T HR P20161541 T1 HRP20161541 T1 HR P20161541T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- alkyl
- independently
- het
- image
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims 63
- 150000002367 halogens Chemical class 0.000 claims 63
- 150000001875 compounds Chemical class 0.000 claims 38
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000003342 alkenyl group Chemical group 0.000 claims 15
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 6
- -1 6-oxopiperidinyl Chemical group 0.000 claims 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 4
- 229910020008 S(O) Inorganic materials 0.000 claims 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (38)
1. Spoj Formule I,
[image]
ili neka njegova farmaceutski prihvatljiva sol, naznačen time, što su
R1 je H, -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil,-C2-C5 alkinil,
-OC2-C5 alkinil, -OH, halogen, -CN, -NR6R7, -CO2R8, -C(O)NR6R7, -SO2NR6R7, HET(3) ili C3-6 cikloalkil, koji po izboru ima 1-2 dvogube veze, pri čemu je svaki od
-C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil i -OC2-C5 alkinil po izboru supstituiran sa 1-7 halogena, a HET(3) i C3-6 cikloalkil, koji po izboru ima 1-2 dvogube veze, su po izboru supstituirani sa 1-3 grupe supstituenata, od kojih je svaka nezavisno, halogen, -C1-C3 alkil, -OC1-C3 alkil, -C2-C3 alkenil, -OC2-C3 alkenil, -C2-C3 alkinil ili -OC2-C3 alkinil, gdje je svaki od -C1-C3 alkil, -OC1-C3 alkil, -C2-C3 alkenil,
-OC2-C3 alkenil, -C2-C3 alkinil i -OC2-C3 alkinil, po izboru supstituiran sa 1-7 halogena;
R6 i R7 su, svaki nezavisno, H ili -C1-C5 alkil;
R8 je H ili -C1-5 alkil, po izboru supstituiran sa 1-7 halogena;
HET(3) je neki 3-6 člani heterociklični prsten, koji ima 1-3 grupe heteroatoma, od kojih je svaka nezavisno N, NH, O, S, S(O) ili S(O)2 i koji po izboru ima 1-3 dvogube veze;
x je 0 ili 1;
Isprekidane linije u Formuli I predstavljaju jednu po izboru dvogubu vezu između dva susjedna atoma kisika;
D1 je N ili CR2;
D2 je N ili CR3;
D3 je N ili CR4;
R2, R3 i R4 su, svaki nezavisno, H, -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil, -OC2-C5 alkinil, -OH, halogen, -CN, -NR6R7, -CO2R8,
-C(O)NR6R7 ili -SO2NR6R7, pri čemu je svaki -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil i -OC2-C5 alkinil po izboru supstituiran sa 1-7 halogena;
R5, svaki nezavisno, je -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil,
-C2-C5 alkinil, -OC2-C5 alkinil, -OH, halogen, -CN, -NR6R7, -CO2R8, -C(O)NR6R7 ili
-SO2NR6R7, pri čemu je svaki -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil i -OC2-C5 alkinil po izboru supstituiran sa 1-7 halogena;
A1 je fenil, HET(1) ili C3-C8 cikloalkil, koji po izboru ima 1-2 dvogube veze, pri čemu je A1 po izboru supstituiran sa jednom supstituentskom grupom Z i po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil,
-OC2-C5 alkenil, -C2-C5 alkinil, -OC2-C5 alkinil, halogen, -OH ili -CN, gdje je svaki -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil i -OC2-C5 alkinil po izboru supstituiran sa 1-7 halogena;
Svaki HET(1) je neki 5- ili 6-člani heterociklični prsten, koji ima 1-4 grupe heteroatoma, od kojih je svaka nezavisno -N-, -NH-, -S-, -O-, -S(O)- ili -S(O)2-, koji po izboru ima jednu grupu -C(=O)- i koji po izboru ima 1-3 dvogube veze;
Z je A3, -C1-C3alkilen-CO2R8, -C1-C3alkilen-C(O)NR6R7, -C1-C3alkilen-SO2NR6R7,
-CO2R8, -C(O)NR6R7, -SO2NR6R7 ili -C1-C3alkilen-HET(2), gdje je -C1-C3alkilen u svim slučajevima po izboru supstituiran sa 1-7 halogena, a HET(2) je po izboru supstituiran sa 1-3 supstituenta, od kojih je svaki nezavisno -C1-3alkil po izboru supstituiran sa 1-5 halogena, -OC1-3alkil po izboru supstituiran sa 1-5 halogena, halogen ili NR6R7;
A3 je fenil, C3-C6 cikloalkil, koji po izboru ima 1-2 dvogube veze, ili HET(1), pri čemu je A3 po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno -C1-C5 alkil,
-OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil, -OC2-C5 alkinil, halogen,
-OH ili -CN, pri čemu je svaki -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5 alkinil i -OC2-C5 alkinil po izboru supstituiran sa 1-7 halogena; i A3 je po izboru supstituiran sa jednom grupom HET(2), -C1-4alkilen-CO2R8, -C1-4alkilen-C(O)NR6R7, -C1-C4alkilen-SO2NR6R7, -CO2R8, -C(O)NR6R7 ili -SO2NR6R7, pri čemu je -C1-C4alkilen u svim slučajevima po izboru supstituiran sa 1-7 halogena; i gdje je HET(2) po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno halogen,
-C1-5alkil, po izboru supstituiran sa 1-7 halogena, -OC1-5alkil, po izboru supstituiran sa 1-7 halogena ili NR6R7;
HET(2) je neki 5-6 člani heterociklični prsten, koji ima 1-3 grupe heteroatoma, od kojih je svaka nezavisno N, NH, O ili S, koji po izboru ima jednu grupu -C(=O)- i koji po izboru ima 1-3 dvogube veze;
A2 je fenil ili HET(1), gdje je A2 po izboru supstituiran sa 1-3 grupe supstituenata, od kojih je svaka nezavisno, -C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil,
-C2-C5 alkinil, -OC2-C5 alkinil, halogen, -CN, -OH ili C3-6cikloalkil, pri čemu je svaki
-C1-C5 alkil, -OC1-C5 alkil, -C2-C5 alkenil, -OC2-C5 alkenil, -C2-C5alkinil i -OC2-C5alkinil po izboru supstituiran sa 1-7 halogena, a C3-6cikloalkil je po izboru supstituiran sa 1-3 supstituenta, od kojih je svaki nezavisno halogen, -C1-C3 alkil ili -OC1-C3 alkil, gdje je -C1-C3 alkil i -OC1-C3 alkil, svaki po izboru, supstituiran sa 1-7 halogena; i
a je 0 ili cijeli broj od 1-3.
2. Spoj ili neka njegova farmaceutski prihvatljiva sol, prema Zahtjevu 1, naznačen time što su:
R1 je -C1-C5 alkil, -OC1-C5 alkil, halogen, -NR6R7, HET(3) ili C3-6 cikloalkil, koji po izboru ima 1-2 dvogube veze, gdje je svaki -C1-C5 alkil i -OC1-C5 alkil po izboru supstituiran sa 1-7 halogena, pri čemu su HET(3) i C3-6 cikloalkil, koji po izboru ima 1-2 dvogube veze, po izboru supstituirani sa 1-3 grupe supstituenata, od kojih je svaka nezavisno halogen, CH3, CF3, OCH3 ili OCF3;
Najmanje jedan od D1, D2 ili D3 je CR2, CR3 ili CR4;
R2, R3 i R4 su, svaki nezavisno, H, -C1-C5 alkil, -OC1-C5 alkil ili halogen, gdje su -C1-C5 alkil i -OC1-C5 alkil po izboru supstituirani sa 1-7 halogena;
R5, svaki nezavisno, je -C1-C5 alkil, -OC1-C5 alkil ili halogen, gdje su -C1-C5 alkil i
-OC1-C5 alkil po izboru supstituirani sa 1-7 halogena;
A1 je fenil, HET(1) ili C3-C6 cikloalkil, koji po izboru ima 1-2 dvogube veze, pri čemu je A1 po izboru supstituiran sa jednom supstituentskom grupom Z i po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno, halogen, -OH, -CN, -C1-5alkil, po izboru supstituiran sa 1-7 halogena ili -OC1-5alkil, po izboru supstituiran sa 1-7 halogena;
A3 je fenil, C3-C6 cikloalkil, koji po izboru ima 1-2 dvogube veze, ili HET(1), pri čemu je A3 po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno -C1-C5 alkil, po izboru supstituiran sa 1-7 halogena, -OC1-C5 alkil, po izboru supstituiran sa 1-7 halogena, -OH ili halogen, i po izboru supstituiran sa jednom grupom koja je HET(2),
-C1-2alkilen-CO2R8, -C1-2alkilen-C(O)NR6R7, -C1-C2alkilen-SO2NR6R7, -CO2R8,
-C(O)NR6R7 ili -SO2NR6R7, gdje je -C1-C2alkilen po izboru supstituiran sa 1-3 halogena; i gdje je HET(2) po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno, halogen, -C1-5alkil, po izboru supstituiran sa 1-7 halogena, -OC1-5alkil, po izboru supstituiran sa 1-7 halogena ili NR6R7; i
A2 je fenil ili HET(1), pri čemu je A2 po izboru supstituiran sa 1-3 grupe supstituenata od kojih je svaka nezavisno C1-5alkil, po izboru supstituiran sa 1-7 halogena. -OC1-5 alkil, po izboru supstituiran sa 1-7 halogena, halogen, -OH, -CN ili C3-6cikloalkil, po izboru supstituiran sa 1-3 supstituenta, od kojih je svaki nezavisno, halogen, CF3, CH3, -OCF3 ili -OCH3.
3. Spoj ili neka njegova farmaceutski prihvatljiva sol prema Zahtjevu 2, naznačen time, što su:
R1 je CH3, CF3, -OCH3, -OCF3, halogen ili -NR6R7;
R6 i R7 su, svaki nezavisno, H ili -C1-C3 alkil;
R2, R3 i R4 su, svaki nezavisno, H, C1-3alkil, CF3, -OC1-3alkil, -OCF3 ili halogen;
R5, svaki nezavisno, je CH3, CF3, -OCH3, -OCF3 ili halogen;
A1 je fenil, HET(1) ili C3-C6 cikloalkil, koji po izboru ima 1-2 dvogube veze, pri čemu je A1 po izboru supstituiran sa jednom supstituentskom grupom Z i po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno, -C1-3alkil, po izboru supstituiran sa 1-5 halogena, -OC1-3alkil, po izboru supstituiran sa 1-5 halogena, halogen, -OH ili -CN;
HET(1), svaki je neki 5- ili 6-člani heterociklični prsten, koji ima 1-3 grupe heteroatoma, od kojih je svaka nezavisno -N-, -NH-, -S- ili -O-, koji po izboru ima jednu grupu -C(=O)- i koji po izboru ima 1-3 dvogube veze;
Z je A3, -(CH2)1-3-CO2R8, -(CH2)1-3-C(O)NR6R7, -(CH2)1-3-SO2NR6R7, -CO2R8,
-C(O)NR6R7, -SO2NR6R7 ili -(CH2)1-3-HET(2), gdje je HET(2) po izboru supstituiran sa 1-3 supstituenta koji su nezavisno -C1-3alkil, po izboru supstituiran sa 1-5 halogena,
-OC1-3alkil, po izboru supstituiran sa 1-5 halogena, halogen ili NR6R7;
R8 je H ili -C1-3alkil, po izboru supstituiran sa 1-3 halogena;
A3 je fenil, C3-C6 cikloalkil, koji po izboru ima 1-2 dvogube veze, ili HET(1), pri čemu je A3 po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno CH3, CF3, -OCH3, -OCF3, -OH ili halogen i po izboru supstituiran sa jednom grupom koja je HET(2), (CH2)1-2-CO2R8, -(CH2)1-2-C(O)NR6R7, -(CH2)1-2-SO2NR6R7, -CO2R8, -C(O)NR6R7 ili
-SO2NR6R7 i HET(2) je po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno, CH3, CF3, -OCH3, -OCF3, halogen ili NR6R7;
A2 je fenil ili HET(1), pri čemu je A2 supstituiran sa 1-3 grupe supstituenata, od kojih je svaka nezavisno CH3, CF3, -OCH3, -OCF3, halogen, -CN, -OH ili C3-4cikloalkil, po izboru supstituiran sa 1-3 supstituenta, od kojih je svaki nezavisno, halogen, CF3, CH3, -OCF3 ili -OCH3; i
a je 0, 1 ili 2.
4. Spoj prema Zahtjevu 3, koji ima Formulu Ia,
[image]
ili neka njegova farmaceutski prihvatljiva sol, naznačen time, što isprekidana linija u prstenu Formule Ia predstavlja po izboru dvogubu vezu.
5. Spoj prema Zahtjevu 4, ili neka njegova farmaceutski prihvatljiva sol, naznačen time, što su:
R1 je CH3, CF3, -OCH3, -OCF3, F, Cl ili -NR6R7;
D1 je N ili CR2, gdje R2 predstavlja H, -C1-3alkil, F ili Cl;
D2 je N ili CR3, gdje R3 predstavlja H, -C1-3alkil, F ili Cl;
D3 je N ili CR4, gdje R4 predstavlja H, -C1-3alkil, F ili Cl;
Najmanje jedan od D1, D2 ili D3 predstavlja CR2, CR3 ili CR4;
R5 je H ili CH3;
A1 je fenil, piridil, pirazinil, pirimidinil, piridazinil, pirazolil, imidazolil, izoksazolil, tiazolil, oksadiazolil, tiadiazolil, oksazolil, pirolil, tienil, furil, ciklopropil, ciklobutil, cikloheksil, cikloheksenil, ciklopentil ili ciklopentenil, pri čemu je A1 po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno F, Cl, -OCH3, -OCF3, -C1-3alkil, -CN ili CF3 i po izboru sa jednom supstituentskom grupom Z;
Z je A3, -CH2CH2CO2R8, -CH2CH2C(O)NR6R7, -CH2CH2SO2NR6R7 ili -CH2CH2-HET(2), gdje je HET(2) po izboru supstituiran sa 1-2 grupe supstituenata, od kojih je svaka nezavisno CH3, CF3, -OCH3,-OCF3, halogen ili NR6R7;
R8 je H ili -CH3;
HET(2) je a 5-člani heterociklični prsten, koji ima 1-3 grupe heteroatoma, od kojih je svaka nezavisno N, NH, O ili S, koji po izboru ima jednu grupu -C(=O) i koji po izboru ima 1-3 dvogube veze;
A3 je fenil, ciklopropil, ciklobutil, cikloheksil, cikloheksenil, ciklopentil, ciklopentenil ili HET(1), gdje je HET(1) piridinil, pirazinil, pirimidinil, piridazinil, pirazolil, imidazolil, izoksazolil, tiazolil, oksadiazolil, tiadiazolil, oksazolil, pirolil, tienil, furil ili neki 5-6-člani heterociklični prsten, koji ima 1-2 grupe heteroatoma, koje su nezavisno -N-, -NH- ili -O- i po izboru jednu -C(=O)- grupu, pri čemu je A3 po izboru supstituiran sa 1-2 grupe, od kojih je svaka nezavisno CH3, CF3, -OCH3, -OCF3, -OH ili halogen i po izboru supstituiran sa 1 grupom koja je -CO2R8, -C(O)NR6R7, -SO2NR6R7 ili HET(2), gdje je HET(2) po izboru supstituiran sa 1-2 grupe supstituenata, od kojih je svaka nezavisno CH3, CF3, -OCH3; -OCF3, halogen ili NR6R7;
A2 je fenil ili HET(1), pri čemu je A2 supstituiran sa 1-3 grupe supstituenata, od kojih je svaka nezavisno CF3, CH3, F, Cl, -CN ili ciklopropil; i
a je 0 ili 1.
6. Spoj prema Zahtjevu 5, ili neka njegova farmaceutski prihvatljiva sol, naznačen time, što:
Isprekidana linija u prstenu Formule Ia predstavlja po izboru dvogubu vezu, kada je x jednako 0;
R1 je CF3, F ili -N(CH3)2;
D1 je N ili CR2, gdje R2 predstavlja H ili C1-3alkil;
D2 je N ili CR3, gdje R3 prtedstavlja H ili CH3;
D3 je N ili CR4, gdje R4 predstavlja H ili CH3;
A1 je fenil, piridil, tienil, furil, cikloheksenil ili ciklopentenil, pri čemu je A1 po izboru supstituiran sa 1-3 grupe, od kojih je svaka nezavisno F, Cl, -OCH3, izopropil, -CN,
-CH3 ili CF3 i po izboru jedna supstituentska grupa Z;
Z je A3, -CH2CH2CO2R8, -CH2CH2-(5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il) ili
-CH2CH2-(5-amino-1,3,4-oksadiazol-2-il);
R8 je H ili -CH3;
A3 je fenil, ciklobutil, ciklopentil, cikloheksil ili HET(1), gdje je HET(1) piridinil, 6-oksopiperidinil, 2-okso-1,3-oksazolidinil, 2-okso-1,3-oksazinanil ili 5-oksopirolidinil, pričemu je A3 po izboru supstituiran sa 1-2 grupe -CH3, -OCH3 ili -OH i po izboru supstituiran sa 1 grupom -(5-okso-4,5-dihidro-1,3,4-oksadiazol-2-il), -(5-amino-1,3,4-oksadiazol-2-il) ili -CO2R8;
A2 je fenil, koji je supstituiran sa 1-2 grupe supstituenata, od kojih je svaka nezavisno CF3, CH3, F ili Cl; i
a je 0.
7. Spoj prema zahtjevu 6, koji ima niže prikazanu strukturu:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
8. Spoj prema Zahtjevu 1, koji ima niže prikazanu strukturu:
[image]
ili neka njegova farmaceutski prihvatljiva sol.
9. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
10. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
11. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
12. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
13. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
14. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
15. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
16. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
17. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
18. Spoj prema zahtjevu 8, ili neka njegova farmaceutski prihvatljiva sol, koji ima strukturu:
[image]
19. Spoj prema Zahtjevu 1 koji ima niže prikazanu strukturu :
[image]
20. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
21. Spoj prema Zahtjevu 19 koji ima strukturu
[image]
22. Spoj prema Zahtjevu 19 kojie ima strukturu:
[image]
23. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
24. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
25. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
26. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
27. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
28. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
29. Spoj prema Zahtjevu 19 koji ima strukturu:
[image]
30. Farmaceutski pripravak, naznačen time, što sadrži terapeutski efikasnu količinu spoja prema bilo kojem od prethodnih Zahtjeva, neku njegovu farmaceutski prihvatljivu sol i neki farmaceutski prihvatljiv nosač.
31. Uporaba u terapiji spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli.
32. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u tretiranju ateroskleroze.
33. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u podizanju HDL-C.
34. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u snižavanju LDL-C.
35. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u tretiranju dislipidemije.
36. Uporaba spoja prema bilo kojem od Zahtjeva 1 do 29, ili neke njegove farmaceutski prihvatljive soli u tretiranju ateroskleroze, periferne vaskularne bolesti, dislipidemije, hiperbetalipoproteinemije, hipoalfalipoproteinemije, hiper-kolesterolemije, hipertrigliceridemije, obiteljske-hiperkolesterolemije, kardio-vaskularnih poremećaja, angine, ishemije, srčane ishemije, moždanog udara, infarkta miokarda, reperfuzijske ozljede, angioplastne restenoze, hipertenzije, vaskularne komplikacije od dijabetesa, pretjerane debljine, endotoksemije ili metaboličkog sindroma; ili u prevenciji ili odgađanju napredovanja Alzheimer-ove bolesti ili drugih neurodegenerativnih bolesti.
37. Kombinacija koja sadrži Spoj prema bilo kojem od Zahtjeva 1 do 29, ili neku njegovu farmaceutski prihvatljivu sol, i druge lijekove.
38. Uporaba kombinacije koja sadrži Spoj prema bilo kojem od Zahtjeva 1 to 29, ili neku njegovu farmaceutski prihvatljivu sol i druge lijekove u tretiranju ateroskleroze, periferne vaskularne bolesti, dislipidemije, hiperbetalipoproteinemije, hipoalfalipoproteinemije, hiperkolesterolemije, hipertrigliceridemije, obiteljske-hiperkolesterolemije, kardiovaskularnih poremećaja, angine, ishemije, srčane ishemije, moždanog udara, infarkta miokarda, reperfuzijske ozljede, angioplastne restenoze, hipertenzije, vaskularne komplikacije od dijabetesa, pretjerane debljine, endotoksemije ili metaboličkog sindroma; prevencije ili odgađanja napredovanja Alzheimer-ove bolesti ili drugih neurodegenerativnih boleti; ili podizanju HDL-C ili snižavanju LDL-C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552592P | 2011-10-28 | 2011-10-28 | |
PCT/US2012/061842 WO2013063217A1 (en) | 2011-10-28 | 2012-10-25 | Fused bicyclic oxazolidinone cetp inhibitor |
EP12781551.2A EP2771345B1 (en) | 2011-10-28 | 2012-10-25 | Fused bicyclic oxazolidinone cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161541T1 true HRP20161541T1 (hr) | 2016-12-30 |
Family
ID=47143312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161541TT HRP20161541T1 (hr) | 2011-10-28 | 2016-11-21 | Fuzionirani biciklični oksazolidinon kao inhibitor cetp |
Country Status (41)
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US9221834B2 (en) | 2010-10-29 | 2015-12-29 | Merck Sharp & Dohme Corp. | Cyclic amine substituted oxazolidinone CETP inhibitor |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
WO2014099836A1 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | Spirocyclic cetp inhibitors |
WO2014099834A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Therapeutic thiazolidinone compounds |
NZ708079A (en) * | 2013-01-31 | 2016-07-29 | Chong Kun Dang Pharm Corp | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
WO2015017302A2 (en) | 2013-07-30 | 2015-02-05 | Merck Sharp & Dohme Corp. | Bicyclic ureas and thiadiazolidine-1,1-dioxides as cetp inhibitors |
US9937153B2 (en) * | 2013-08-30 | 2018-04-10 | Merck Sharp & Dohme Ltd. | Oral pharmaceutical formulation of omarigliptin |
WO2015054088A1 (en) | 2013-10-10 | 2015-04-16 | Merck Sharp & Dohme Corp. | 3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein |
WO2015094932A1 (en) * | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
BR112016018077A8 (pt) | 2014-02-05 | 2020-06-23 | Dezima Pharma B V | inibidor de proteína de transferência de éster colesterílico (composto a), composições farmacêuticas compreendendo o mesmo, método para preparação das referidas composições e uso do composto a |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
CA2943682C (en) | 2014-03-26 | 2024-02-13 | Astex Therapeutics Ltd | Combinations of fgfr and cmet inhibitors and their use for the treatmentof cancer |
CN106456648B (zh) | 2014-03-26 | 2021-11-02 | 阿斯特克斯治疗有限公司 | Fgfr抑制剂和igf1r抑制剂的组合 |
EP3174537B1 (en) | 2014-07-29 | 2021-06-23 | Merck Sharp & Dohme Corp. | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein |
WO2016067194A1 (en) * | 2014-10-27 | 2016-05-06 | Sun Pharmaceutical Industries Limited | Process for the preparation of anacetrapib and an intermediate thereof |
US20170252338A1 (en) * | 2014-11-28 | 2017-09-07 | Kowa Company, Ltd. | Medicine |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
WO2016201310A1 (en) * | 2015-06-12 | 2016-12-15 | Rhodia Operations | Hybrid nanoparticles containing dendrons, methods of producing such hybrid nanoparticles, and uses thereof |
EP3322420B1 (en) | 2015-07-13 | 2021-12-29 | Merck Sharp & Dohme Corp. | Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein |
HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
SI3353177T1 (sl) | 2015-09-23 | 2020-08-31 | Janssen Pharmaceutica Nv | Triciklični heterocikli za zdravljenje raka |
CN106432053A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种尼拉帕布中间体4‑(3s‑哌啶‑3‑基)溴苯的制备方法 |
CN106432058A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种Niraparib中间体4‑(3S‑哌啶‑3‑基)苯胺的制备方法 |
CN111285894B (zh) * | 2018-12-10 | 2021-03-05 | 北京天一绿甫医药科技有限公司 | 用于制备软海绵素类化合物的中间体及其制备方法 |
CN110639018B (zh) * | 2019-11-14 | 2020-06-26 | 牡丹江医学院 | 一种防治老年性高血压的药物组合物及其用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
AU2001277056B2 (en) | 2000-07-25 | 2005-09-29 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
CA2434491A1 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
EP1414795A4 (en) | 2001-07-31 | 2006-03-01 | Bristol Myers Squibb Co | BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR |
WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
KR20050057074A (ko) | 2002-08-29 | 2005-06-16 | 머크 앤드 캄파니 인코포레이티드 | 항당뇨 활성을 갖는 인돌 |
US7319170B2 (en) | 2003-01-17 | 2008-01-15 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzensulfonmide derivatives |
WO2004112699A2 (en) | 2003-06-12 | 2004-12-29 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2005018638A1 (en) | 2003-08-13 | 2005-03-03 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CN1938320A (zh) * | 2004-03-26 | 2007-03-28 | 伊莱利利公司 | 用于治疗异常脂肪血症的化合物和方法 |
US20070208003A1 (en) | 2004-03-26 | 2007-09-06 | Bell Michael G | Compounds and methods for treating dyslipidemia |
JP4922924B2 (ja) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害薬 |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
EP1966203B1 (en) | 2005-12-22 | 2013-11-13 | Merck Sharp & Dohme Corp. | Oxazoloisoquinoline derivatives as thrombin receptor antagonists |
US7781426B2 (en) | 2005-12-30 | 2010-08-24 | Merck Sharp & Dohme Corp. | CETP inhibitors |
CA2635083C (en) | 2005-12-30 | 2014-10-28 | Merck & Co., Inc. | Oxazolidinone derivatives as cetp inhibitors |
WO2007079186A2 (en) | 2005-12-30 | 2007-07-12 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
US8354454B2 (en) | 2008-10-01 | 2013-01-15 | Merck Sharp & Dohme Corp. | Prodrugs of oxazolidinone CETP inhibitors |
WO2011028395A1 (en) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Pyridyl oxazolidinone cetp inhibitor |
US9221834B2 (en) | 2010-10-29 | 2015-12-29 | Merck Sharp & Dohme Corp. | Cyclic amine substituted oxazolidinone CETP inhibitor |
EP2844252B1 (en) | 2012-05-02 | 2016-11-30 | Merck Sharp & Dohme Corp. | Cyclic amine substituted heterocyclic compounds as cetp inhibitors |
-
2012
- 2012-10-21 JO JOP/2012/0317A patent/JO3210B1/ar active
- 2012-10-25 BR BR112014010204A patent/BR112014010204A2/pt not_active Application Discontinuation
- 2012-10-25 IN IN3073CHN2014 patent/IN2014CN03073A/en unknown
- 2012-10-25 PT PT127815512T patent/PT2771345T/pt unknown
- 2012-10-25 JP JP2014538988A patent/JP5658427B2/ja not_active Expired - Fee Related
- 2012-10-25 ES ES12781551.2T patent/ES2604953T3/es active Active
- 2012-10-25 EA EA201490889A patent/EA026123B1/ru not_active IP Right Cessation
- 2012-10-25 SG SG11201401884PA patent/SG11201401884PA/en unknown
- 2012-10-25 UA UAA201405743A patent/UA114612C2/uk unknown
- 2012-10-25 PE PE2014000616A patent/PE20141230A1/es not_active Application Discontinuation
- 2012-10-25 CN CN201280052931.5A patent/CN103958524B/zh not_active Expired - Fee Related
- 2012-10-25 RS RS20161003A patent/RS55420B1/sr unknown
- 2012-10-25 GE GEAP201213478A patent/GEP20166434B/en unknown
- 2012-10-25 KR KR1020147013895A patent/KR101686308B1/ko active IP Right Grant
- 2012-10-25 EP EP12781551.2A patent/EP2771345B1/en active Active
- 2012-10-25 PL PL12781551T patent/PL2771345T3/pl unknown
- 2012-10-25 CA CA2852743A patent/CA2852743C/en not_active Expired - Fee Related
- 2012-10-25 DK DK12781551.2T patent/DK2771345T3/en active
- 2012-10-25 LT LTEP12781551.2T patent/LT2771345T/lt unknown
- 2012-10-25 US US13/660,010 patent/US8871738B2/en active Active
- 2012-10-25 AU AU2012328759A patent/AU2012328759B2/en not_active Ceased
- 2012-10-25 HU HUE12781551A patent/HUE030568T2/en unknown
- 2012-10-25 SI SI201230757A patent/SI2771345T1/sl unknown
- 2012-10-25 ME MEP-2016-268A patent/ME02557B/me unknown
- 2012-10-25 MX MX2014005074A patent/MX345222B/es active IP Right Grant
- 2012-10-25 WO PCT/US2012/061842 patent/WO2013063217A1/en active Application Filing
- 2012-10-26 TW TW101139812A patent/TWI601731B/zh not_active IP Right Cessation
- 2012-10-26 AR ARP120104037A patent/AR088565A1/es unknown
-
2014
- 2014-04-13 IL IL232130A patent/IL232130A/en not_active IP Right Cessation
- 2014-04-15 TN TNP2014000158A patent/TN2014000158A1/en unknown
- 2014-04-22 CO CO14085787A patent/CO6940419A2/es active IP Right Grant
- 2014-04-25 DO DO2014000086A patent/DOP2014000086A/es unknown
- 2014-04-25 ZA ZA2014/03091A patent/ZA201403091B/en unknown
- 2014-04-28 CL CL2014001090A patent/CL2014001090A1/es unknown
- 2014-04-28 NI NI201400034A patent/NI201400034A/es unknown
- 2014-05-13 MA MA37024A patent/MA35643B1/fr unknown
- 2014-05-28 CR CR20140256A patent/CR20140256A/es unknown
- 2014-05-28 EC ECIEPI20142458A patent/ECSP14002458A/es unknown
- 2014-09-04 HK HK14109018.3A patent/HK1195558A1/zh not_active IP Right Cessation
- 2014-09-08 US US14/480,202 patent/US9346825B2/en active Active
- 2014-09-18 ZA ZA2014/06833A patent/ZA201406833B/en unknown
-
2016
- 2016-11-21 HR HRP20161541TT patent/HRP20161541T1/hr unknown
- 2016-12-16 CY CY20161101308T patent/CY1118464T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161541T1 (hr) | Fuzionirani biciklični oksazolidinon kao inhibitor cetp | |
HRP20211011T1 (hr) | N-[4-fluor-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oksadiazol-3-il)metoksi]-1-piperidil]metil]tiazol-2-il]acetamid kao inhibitor oga | |
JP2016535732A5 (hr) | ||
RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
JP2019517487A5 (hr) | ||
HRP20200601T1 (hr) | Inhibiranje ionskog kanala za prolazni receptorski potencijal a1 | |
EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
JP2017513894A5 (hr) | ||
NZ712180A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis | |
JP2016517417A5 (hr) | ||
HRP20120993T1 (hr) | Anacetrapib i drugi inhibitori cetp | |
AR084222A1 (es) | Derivados de amido-piridina como antagonistas del receptor ep4 | |
JP2015514073A5 (hr) | ||
RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
JP2014511892A5 (hr) | ||
HRP20110456T1 (hr) | Derivati indola kao agonisti receptora s1p1 | |
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
JP2013509392A5 (hr) | ||
JP2016520065A5 (hr) | ||
JP2017505293A5 (hr) | ||
RU2017111590A (ru) | Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида | |
JP2015516427A5 (hr) | ||
JP2016528273A5 (hr) | ||
TR201820513T4 (tr) | Roryt modülatörleri olarak tiazoller. | |
SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 |